The second-generation anticholinergic bronchodilator tiotropium (Spiriva) has drawn its share of attention. The once-a-day treatment for chronic obstructive pulmonary disease (COPD) from Boehringer Ingelheim GMBH has been hailed as this year's most important new Big Pharma drug, with some analyst predicting peak sales in excess of $2 billion. They've been encouraged by Spiriva's European roll-out, which began in June: the drug is now available on more than a dozen markets worldwide. An FDA decision is expected at any moment—following a unanimous advisory committee recommendation.
Spiriva's success was expected. Until Pfizer Inc. finally won the competition, signing a worldwide marketing partnership for the drug,...




